cARdiotoxicity Profile of aBIraTeRone in prostAte Cancer : a pharmacoviGilancE Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1717 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-05-16

Study Completion Date

2017-07-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Abiraterone associated with prednisone is used in prostate cancer. Abiraterone is a selective small-molecule inhibiting cytochrome P450 17A1 (CYP17A1), a key enzyme in androgen synthesis.

CYP17A inhibition is also responsible for mineral corticosteroid related adverse events as hypokaliemia, fluid retention, and hypertension. Primary hyperaldosteronism is associated with cardiovascular toxicities such as atrial fibrillation and cardiac failure. Other androgen-deprivation therapies are not associated with increased mineral corticosteroid level.

This study investigates reports of cardiovascular toxicities for treatment including L02 (sex hormones used in treatment of neoplastic diseases), and G03 (sex hormones) used in prostate cancer in the French pharmacovigilance database and in the EudraCT database.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer

NCT01023061

Adenocarcinoma of the Prostate Stage II Prostate Cancer Stage III Prostate Cancer +1 more

COMPLETED PHASE2

Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer

NCT06173362

Advanced Prostate Adenocarcinoma Stage III Prostate Cancer AJCC v8 Stage IV Prostate Cancer AJCC v8

RECRUITING PHASE2

Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer

NCT00473746

Prostate Neoplasms

COMPLETED PHASE1/PHASE2

An Efficacy and Safety Study of Abiraterone Acetate and Prednisone in Participants With Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy

NCT00485303

Prostatic Neoplasms Prostate Cancer

COMPLETED PHASE2

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer

NCT00924469

Prostate Cancer

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Due to its peculiar pharmacology, abiraterone is potentially associated with more cardiotoxicity as compared to other androgen-deprivation therapies. This study investigates the main characteristics of patients affected by cardiovascular side effects of which supraventricular arrhythmias (including atrial fibrillation, atrial flutter, supraventricular tachycardia), and cardiac failure imputed to drugs classified as L02, and G03 according to anatomical therapeutic chemical (ATC) classification. A causality assessment according to the World Health Organization-The Uppsala Monitoring Centre (WHO-UMC) is systematically applied.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Arrhythmias, Cardiac Atrial Fibrillation and Flutter Tachycardia, Supraventricular Cardiac Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

L02 (sex hormones used in treatment of neoplastic diseases) and G03 (sex hormones)

Androgen-deprivation therapies including L02 (sex hormones used in treatment of neoplastic diseases), and G03 (sex hormones)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Case reported in the French pharmacovigilance database from 01/01/1985 to 16/05/2017
* Case reported in the EudraCT database to May 2017
* Adverse event reported were including the MedDRA terms: SOC Cardiac Disorders; SOC Vascular Disorders; HLT Death, Sudden Death; HLGT Water, electrolyte and mineral investigations; HLGT Cardiac and vascular investigations (excl enzyme tests); and PT Syncope.
* Patients treated with hormonal therapies included in the ATC L02, and G03